Search / Trial NCT06616506

Artificial Intelligence for Highly Myopic Cataract

Launched by SHANGHAI HIGH MYOPIA STUDY GROUP · Sep 25, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Highly Myopic Cataract Artificial Intelligence Cataract Big Data

Description

High myopia cataract (HMC) is a complex cataract with high risk of blindness. At present, there are nearly 300 million people with high myopia in the world, which will increase to 500 million by 2020. Asia is the high incidence of myopia in the world. At present, there are more than 500 million people with myopia in China alone, of which nearly 100 million are high myopia, and this number is still growing rapidly. Correspondingly, the incidence rate of cataract with high myopia has also increased rapidly, which accounts for over 40% of cataract surgery. In the early stage of the project te...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Axial length ≥ 26 mm and patients with high myopia complicated by cataracts who visit our hospital.
  • Preoperative anterior segment photography and cataract severity assessment, along with fundus OCT examination, have been performed.
  • If surgical treatment is conducted, the postoperative follow-up period should be no less than 1 month.
  • There are no missing clinical data before and after the surgery.
  • Exclusion Criteria:
  • Patients who are unable to cooperate with the required examinations for this study.

About Shanghai High Myopia Study Group

The Shanghai High Myopia Study Group is a collaborative research consortium dedicated to investigating the epidemiology, etiology, and management of high myopia, a significant public health concern in urban populations. Comprising a multidisciplinary team of ophthalmologists, optometrists, and public health experts, the group conducts innovative clinical trials and observational studies aimed at understanding the progression of myopia and developing effective interventions. By leveraging advanced imaging technologies and longitudinal data collection, the group strives to enhance clinical practices and inform public health strategies to mitigate the impact of high myopia on visual health in the community.

Locations

Shanghai, Shanghai, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0